- Home
- HURA vs BTMD Comparison
HURA vs BTMD Comparison
Compare HURA & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- BTMD
- Stock Information
- Founded
- HURA 2009
- BTMD 2012
- Country
- HURA United States
- BTMD United States
- Employees
- HURA N/A
- BTMD N/A
- Industry
- HURA
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- HURA
- BTMD Health Care
- Exchange
- HURA Nasdaq
- BTMD Nasdaq
- Market Cap
- HURA 122.0M
- BTMD 127.8M
- IPO Year
- HURA N/A
- BTMD N/A
- Fundamental
- Price
- HURA $3.06
- BTMD $2.92
- Analyst Decision
- HURA Strong Buy
- BTMD Buy
- Analyst Count
- HURA 2
- BTMD 2
- Target Price
- HURA $11.50
- BTMD $6.00
- AVG Volume (30 Days)
- HURA 773.7K
- BTMD 185.8K
- Earning Date
- HURA 08-14-2025
- BTMD 08-06-2025
- Dividend Yield
- HURA N/A
- BTMD N/A
- EPS Growth
- HURA N/A
- BTMD 642.53
- EPS
- HURA N/A
- BTMD 0.88
- Revenue
- HURA N/A
- BTMD $199,073,000.00
- Revenue This Year
- HURA N/A
- BTMD $5.87
- Revenue Next Year
- HURA N/A
- BTMD $8.59
- P/E Ratio
- HURA N/A
- BTMD $3.39
- Revenue Growth
- HURA N/A
- BTMD 6.32
- 52 Week Low
- HURA $1.80
- BTMD $2.76
- 52 Week High
- HURA $8.63
- BTMD $6.98
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- BTMD 32.79
- Support Level
- HURA N/A
- BTMD $2.76
- Resistance Level
- HURA N/A
- BTMD $3.18
- Average True Range (ATR)
- HURA 0.00
- BTMD 0.25
- MACD
- HURA 0.00
- BTMD -0.12
- Stochastic Oscillator
- HURA 0.00
- BTMD 8.04
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.